Reducing the abundance of MuRF1 and atrogin-1 in skeletal muscles of the tumor and chronic diseases through targeting upstream regulators would likely to attenuate muscle cachexia (Zhang et al., 2018). This evidence concerns the gene FBXO32 and neoplasm.